PD-1/PD-L1 inhibitors show a higher incidence of CIP than other ICIs, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, and are responsible for 35% of CIP-related deaths (9, 14). The gene discussed is CTLA4; the disease is hereditary sensory and autonomic neuropathy.